Rapid Cell-Free Combinatorial Mutagenesis Workflow Using Small Oligos Suitable for High-Iteration, Active Learning-Guided Protein Engineering

This article has been Reviewed by the following groups

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

Log in to save this article

Abstract

Active learning-guided protein engineering e2iciently navigates the challenging fitness landscape by screening designs iteratively in a model-guided design-build-test-learn cycle. However, while high iterations boost performance, current workflows reliance on tedious and costly cell-based cloning and expression steps limits the iterations they can practically implement. To address this problem, we present a novel combinatorial mutagenesis workflow that uses small (∼20-40 bp) mutagenic annealed-oligo fragments and cell-free expression to rapidly and conveniently screen protein variants in <9 hours. Using bulk-prepared mutagenic oligos eliminates the need for cloning, PCR-based mutagenesis, or ordering costly genes each screening round. Their >80% size reduction from current fragment-based shu2ling strategies also helps avoid including multiple mutations on the same fragment, reducing the number one must order to cover the design space. By screening 3-10 fragment assemblies for two di2erent proteins, we show our approach is a general, scalable, and cost-e2ective platform for high-iteration protein engineering.

Article activity feed

  1. Despite these limitations, our oligo-based cell-free screening workflow is well-suited to a wide-range of protein engineering tasks.

    I really like this idea! Not necessarily in this paper, but I'm interested in seeing it stress-tested a bit more in future work. What happens with more complex oligos with more mutations? What happens in different proteins?

  2. This implies that even with misligation products, the assembly fidelity for the complex 10-oligo assembly is sufficient for cell-free protein screening.

    Did you move these ligation products directly into cell-free testing like you did for the previous round, or did you do some kind of purification to eliminate those misligation products?

  3. Specifically, we assayed a common batch size of 96 samples consisting of 6 replicates of 14 mutants, a missing oligo assembly, and a no DNA control.

    Did you include a WT that you assembled similar to how you assembled the mutants?